Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-K: Finerenone vs Alternate-Day Spironolactone in HF and DKD
NCT07523867Phase 4Not yet recruiting
- Sponsor
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of finerenone in heart failure (HF), diabetic kidney disease (DKD), sponsored by Hospital de Messejana Dr. Carlos Alberto Studart Gomes. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
heart failure (HF)diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT07523867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523867.